
Deborah Dunsire set to retire later this year.

Deborah Dunsire set to retire later this year.

Senior editor Fran Pollaro interviews Veeva's Paul Shawah about the dynamic future of field teams in biopharma. The chat highlights the transformative power of data and artificial intelligence (AI) in advancing precision medicine.

Drug expected to support children aged 4 and 5 with Duchenne muscular dystrophy.

Medications expected to improve blood sugar control in children 10 years and older.

Project intends to increase diverse representation in medical imagery.

Medicine created for patients with difficulty swallowing tablets.

Group to be fully integrated into Verix lab.

Initiative to support developing manufacturers launch new products.

Collaboration to focus on personalized medicine in the United Arab Emirates capital.

Pharma giant to absorb oral treatment specialist.

Biopharma aims to strengthen field engagement with healthcare professionals.

Company reportedly on schedule to make drug available in the second half of this year.

Medicine expected to be available immediately via prescription.

Assets include cardiology, otic infections, and pain management.

Research to focus on the treatment of atherosclerotic cardiovascular disease.

Forces pharma giant to hand over marketing communications with Meta.

Expansion expected to create additional production capacity, company says.

Decision based on data collected from patients in the early stages of the disease.

Deal reached with a potential equity value of $3.5 billion.

With the sales boom from COVID-19 products now in the rear-view, a resetting is underway for those in Pharm Exec’s listing of the top biopharma producers—shifting attention to new Rx roads ahead and the steady strategies needed to navigate a bumpy business terrain.

The new era of generative AI is poised to impact pharma marketing and engagement in powerful and lasting ways. But amid all the technological praise, what are the key considerations brand teams must navigate?

Amid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.

Senior editor Fran Pollaro and Morten Nielsen, senior partner for the life sciences practice at Wittkieffer, embark on an insightful exploration of trust in the pharmaceutical industry, discussing its measurement, improvement, and critical role in governance, culture, leadership, and organizational structure, while offering practical advice for industry leaders on embedding transparency, inclusion, and accountability into daily operations.

Transaction expected to provide shareholders with immediate value.

Prevymis to focus on disease in high-risk adult kidney transplant recipients.